JACC: Heart Failure Vol. 1, No. 3, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.00
|
|
- Angela Barber
- 6 years ago
- Views:
Transcription
1 JACC: Heart Failure Vol. 1, No. 3, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.00 Published by Elsevier Inc. Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving Cardiac Resynchronization Therapy Long-Term Follow-Up of w145,000 Patients Zak Loring, BS,*y Daniel A. Caños, MPH,* Kimberly Selzman, MD, MPH,*z Naomi D. Herz, BS,* Henry Silverman, BS,x Thomas E. MaCurdy, PHD,x Christopher M. Worrall, BS,k Jeffrey Kelman, MD, MMSC,k Mary E. Ritchey, PHD,* Ileana L. Piña, MD, MPH,*{ David G. Strauss, MD, PHD* Silver Spring, Maryland; Durham, North Carolina; Salt Lake City, Utah; Burlingame, California; Baltimore, Maryland; and Bronx, New York Objectives Background Methods Results Conclusions The goal of this study was to test the hypothesis that in recipients of cardiac resynchronization therapy defibrillators (CRT-D), conventional left bundle branch block (LBBB) diagnosis predicts better survival in women than in men. New York Heart Association class I and II patients without LBBB do not benefit from CRT-D, and women have better survival after CRT-D than men. Separate analysis suggests that QRS duration thresholds for LBBB diagnosis differ according to sex, and conventional LBBB electrocardiographic criteria are falsely positive in men more frequently than in women. We analyzed Medicare records from 144,642 CRT-D recipients between 2002 and 2008 that were followed up for up to 90 months. Medicare billing data were used to determine age, sex, race, and comorbidities. Hazard ratios (HRs) were calculated to assess if conventional LBBB diagnosis had different prognostic significance according to sex. In univariate analysis, LBBB was associated with a 31% reduction in death in women (HR: 0.69 [95% confidence interval (CI): 0.67 to 0.71]) but only a 16% reduction in death in men (HR: 0.84 [95% CI: 0.82 to 0.85]). In multivariable analyses controlling for comorbidities, LBBB was associated with a 26% reduction in death in women (HR: 0.74 [95% CI: 0.71 to 0.77]) and a 15% reduction in death in men (HR: 0.85 [95% CI: 0.83 to 0.87]). A significant interaction (p < ) between sex and LBBB was seen. LBBB diagnosis is associated with greater survival in women than in men receiving CRT-D, and this discrepancy is not explained by differences in measured comorbidities. Possible explanations for this difference include that LBBB may have different prognostic significance according to sex or that LBBB diagnosis is more often false-positive in men compared with women. (J Am Coll Cardiol HF 2013;1:237 44) ª 2013 by the American College of Cardiology Foundation Cardiac resynchronization therapy defibrillators (CRT-D) reduce mortality and heart failure (HF) hospitalizations in patients with reduced left ventricular (LV) ejection fraction and prolonged QRS duration (QRSD) (1 5). However, recent analysis of clinical trials enrolling New York Heart From the *Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland; yduke University School of Medicine, Durham, North Carolina; zdivision of Cardiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah; xacumen, LLC, SafeRx, Burlingame, California; kcenters for Medicare & Medicaid Services, Baltimore, Maryland; and the {Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York. This project was supported by the Centers for Medicare & Medicaid Services/U.S. Food and Drug Administration (FDA) SafeRx Project and the FDA Office of Women s Health. All authors have reported that they have no relationships relevant to the contents of this paper to disclose. Manuscript received December 17, 2012; revised manuscript received March 4, 2013, accepted March 6, Association class I and II patients found that clinical benefit was greatest in (and in some cases limited to) patients with left bundle branch block (LBBB) (6 8). In addition, analysis of Medicare patients receiving CRT-D in the American College of Cardiology Implantable Cardioverter- Defibrillator Registry demonstrated that LBBB was a strong predictor of both freedom from HF hospitalization and overall survival (9). These findings have prompted interest in developing a better understanding of how to both diagnose LBBB and integrate it into current indications for cardiac resynchronization therapy (CRT) (10,11). Previous studies have demonstrated that women have better long-term survival after CRT than men (12,13). However, subgroup analysis of CRT-D trials to investigate the source of this sex disparity has been limited because women represented only 24% of enrolled patients (14). This underrepresentation
2 238 Loring et al. JACC: Heart Failure Vol. 1, No. 3, 2013 LBBB and Sex in Medicare CRT Patients June 2013: Abbreviations and Acronyms CI = confidence interval CRT = cardiac resynchronization therapy CRT-D = cardiac resynchronization therapy defibrillators HF = heart failure HR = hazard ratio ICD-9-CM = International Classification of Diseases- Ninth Revision-Clinical Modification LBBB = left bundle branch block LV = left ventricular RBBB = right bundle branch block QRSD = QRS duration may cause sex differences in the prognostic value of clinical variables to be overshadowed. A recent meta-analysis found that clinical benefit from CRT-D was limited to patients with QRSD 150 ms (14); however, this finding did not take into account QRS morphology, and QRSD 150 ms may thus be an indirect marker of LBBB, which has been shown to be a better predictor of CRT outcomes than QRSD (11,15). Recent studies have suggested that women with LBBB have shorter QRSD than men because women have smaller ventricles and shorter QRSD in the absence of LBBB (10,16). Thus, limiting CRT-D to patients with QRSD 150 ms may deny CRT-D to women with complete LBBB who are likely to benefit from this device. Endocardial mapping studies have found that one-third of patients diagnosed with LBBB by using conventional electrocardiographic criteria do not have endocardial activation consistent with LBBB (17,18). Separate analysis suggests that QRSD thresholds for LBBB diagnosis differ according to sex and that conventional LBBB electrocardiographic criteria are falsely positive in men more frequently than in women because of their smaller ventricles and shorter QRSD than men (10,16). In the current study, we tested the hypothesis that in CRT-D patients, conventional diagnosis of LBBB would be associated with better long-term survival in women than in men even after accounting for baseline comorbidities. Methods This study was approved by the U.S. Food and Drug Administration Research in Human Subjects Committee and the Centers for Medicare & Medicaid Services. It included all Medicare patients (107,475 male and 37,167 female subjects) who received CRT-D (International Classification of Diseases-Ninth Revision-Clinical Modification [ICD-9- CM] procedure code 0051) between July 1, 2002, and December 31, 2008, who were also continuously enrolled in Medicare Part A (inpatient hospital coverage) and B (outpatient medical coverage) for 6 months before CRT-D implantation. Comorbidities. We compared the prevalence and prognostic significance of demographic data and several comorbidities as documented in Medicare claims files by using ICD-9-CM codes. These variables include age, reason for entrance into Medicare, race, year of device implantation, preexisting comorbidities (previous myocardial infarction, hypertension, LBBB, right bundle branch block [RBBB], ischemic cardiomyopathy, diabetes mellitus, atrial fibrillation/flutter, previous stroke, previous HF hospitalizations, and end-stage renal disease). To account for risk associated with unmeasured comorbidities, we also included the Charlson comorbidity index or Charlson score in all models (19). The Charlson score is an index used to predict 10-year mortality based on whether a patient has certain health conditions; the specific conditions are listed in the Online Appendix. In the Cox proportional hazards models, race was classified as black or non-black. Year of device implantation was defined as the year the procedure code 0051 was recorded in the patient s record. Preexisting comorbidities were assessed by determining if a beneficiary had an ICD-9-CM diagnosis code in the 6 months before CRT-D implantation; the Online Appendix lists the specific ICD-9-CM codes. Outcomes. The primary outcome for this study was allcause mortality. Mortality was determined from the Medicare Master Beneficiary Summary File from the Centers for Medicare & Medicaid Services, which documents date of death for beneficiaries assessed from the Social Security Administration. Secondary analyses were performed for the endpoint all-cause mortality or in-patient HF hospitalization as a primary diagnosis (ICD-9-CM code 428.x). Patients were censored if they did not reach the primary (or secondary) endpoint before December 31, 2009, or if they were no longer continuously enrolled in Medicare Part B. Statistical analyses. Kaplan-Meier curves stratified for sex and LBBB were generated for total survival for up to 72 months of follow-up. The significance of demographic and comorbidity characteristics were assessed in univariate and multivariable Cox proportional hazards models for the total population as well as for men and women independently. The proportional hazards assumption was verified by using plots of the log (-log) survival cures and by using Cox test for continuous time interaction. Multivariable models included age, sex, race, year of device implantation, and all preexisting comorbidities, including the Charlson score. The interactions of sex and each of the comorbidities (including LBBB) were also evaluated to determine if the prognostic value of these comorbidities differed according to sex. All analyses were conducted by using SAS version 9.2 (SAS Institute, Inc., Cary, North Carolina). Results Of the 144,642 Medicare CRT-D patients included in this study, 107,475 (74%) were male and 37,167 (26%) were female (Table 1). Men (compared with women) were more commonly white (90% vs. 84%) and more frequently had ischemic cardiomyopathy (69% vs. 53%) and atrial fibrillation/flutter (56% vs. 48%). Women were more frequently black (13% vs. 7%) and more frequently had LBBB (53% vs. 39%). Other comorbidities (including Charlson score), age, reason for entering Medicare, region of residence, and year of
3 JACC: Heart Failure Vol. 1, No. 3, 2013 June 2013: Loring et al. LBBB and Sex in Medicare CRT Patients 239 Table 1 Baseline Characteristics According to Sex Characteristic Female Subjects (n ¼ 37,167) Male Subjects (n ¼ 107,475) Total (N ¼ 144,642) Comorbidities Myocardial infarction 5,900 (16) 18,234 (17) 24,134 (17) Hypertension 32,346 (87) 90,098 (84) 122,444 (85) LBBB 19,596 (53) 42,328 (39) 61,924 (43) RBBB 1,710 (5) 8,328 (8) 10,038 (7) Ischemic cardiomyopathy 19,580 (53) 74,236 (69) 93,816 (65) Diabetes 17,813 (48) 49,892 (46) 67,705 (47) Atrial fibrillation/flutter 17,858 (48) 60,715 (56) 78,573 (54) Stroke 2,840 (8) 8,005 (7) 10,845 (7) Previous heart failure hospitalization 9,687 (26) 23,405 (22) 33,092 (23) ESRD 869 (2) 2,917 (3) 3,786 (3) Charlson score 0 1,432 (4) 4,531 (4) 5,963 (4) 1 10,477 (28) 26,986 (25) 37,463 (26) 2 11,029 (30) 31,644 (29) 42,673 (30) 3 7,270 (20) 21,679 (20) 28,949 (20) 4 6,959 (19) 22,635 (21) 29,594 (20) Age (yrs) < (<1) 912 (<1) 1,255 (<1) ,038 (3) 3,004 (3) 4,042 (3) ,83 (9) 9,312 (9) 12,495 (9) ,641 (39) 41,098 (38) 55,739 (39) ,623 (42) 46,071 (43) 61,694 (43) >84 2,339 (6) 70,78 (7) 9,417 (7) Race White 31,035 (84) 96,348 (90) 127,383 (88) Black 4,829 (13) 7,711 (7) 12,540 (9) Asian 206 (<1) 622 (<1) 828 (<1) Hispanic 661 (2) 1,426 (1) 2,087 (1) North American Native 192 (<1) 439 (<1) 631 (<1) Other, non-north American Native 217 (<1) 840 (<1) 1,057 (<1) Other/unknown 27 (<1) 89 (<1) 116 (<1) Reason for entrance into Medicare Aged without ESRD 27,752 (75) 75,996 (71) 10,3748 (72) Aged with ESRD 36 (<1) 114 (<1) 150 (<1) Disabled without ESRD 9,165 (25) 30,690 (29) 39,855 (28) Disabled with ESRD 58 (<1) 196 (<1) 254 (<1) ESRD only 120 (<1) 429 (<1) 549 (<1) Unknown 36 (<1) 50 (<1) 86 (<1) Year of CRT-D implantation (<1) 1,219 (1) 1,535 (1) ,088 (8) 11,598 (11) 14,686 (10) ,772 (16) 18,759 (17) 24,531 (17) ,940 (21) 22,412 (21) 30,352 (21) ,476 (20) 19,952 (19) 27,428 (19) ,758 (18) 17,941 (17) 24,699 (17) ,817 (16) 15,594 (15) 21,411 (15) Values are n (%). CRT-D ¼ cardiac resynchronization therapy defibrillator; ESRD ¼ end-stage renal disease; LBBB ¼ left bundle branch block; RBBB ¼ right bundle branch block. CRT-D implantation were similar across sexes. Follow-up data were available for a median of 28 months (interquartile range: 15 to 46 months) with 5,852 patients remaining at 72 months and up to 90 months of follow-up for some patients. After 72 months of follow-up, 57,043 patients (60% of the uncensored population) had died. Women had significantly lower mortality than men (54% vs. 62%) (Fig. 1A), and the separation of these survival curves continued to diverge over the length of follow-up. Patients with LBBB also had lower mortality than those without LBBB (56% vs. 63%) (Fig. 1B). When stratifying according to both sex and LBBB status (Fig. 1C), women with LBBB
4 240 Loring et al. JACC: Heart Failure Vol. 1, No. 3, 2013 LBBB and Sex in Medicare CRT Patients June 2013: Figure 1 Kaplan-Meier Plots of Survival Results are stratified according to (A) sex, (B) left bundle branch block (LBBB), or (C) both. Women had better survival than men, and LBBB patients had better survival than non-lbbb patients. CRT-D ¼ cardiac resynchronization therapy defibrillators. had the lowest mortality (49%), whereas men without LBBB had the highest mortality (64%). Non-LBBB women and LBBB men had intermediate mortalities (59% and 60%, respectively). Univariate and multivariable models for death. Cox proportional hazards for overall mortality were determined for the total population and for men and women independently. Figure 2 contains forest plots of adjusted hazard ratios (HRs); Online Tables 1 and 2 contain univariate and multivariable HRs. In the overall population, all comorbidities (including ischemic cardiomyopathy and atrial fibrillation/flutter) were associated with higher rates of death, with the exception of LBBB, which was associated with an 18% lower rate of death (adjusted HR: 0.82 [95% confidence interval (CI): 0.81 to 0.84]). Presence of end-stage renal disease had the strongest associated mortality rate (adjusted HR: 2.55 [95% CI: 2.46 to 2.67]). Male sex was associated with higher mortality (adjusted HR: 1.19 [95% CI: 1.17 to 1.22]), as was black race (adjusted HR: 1.18 [95% CI: 1.14 to 1.21]). With the exception of hypertension, similar trends were seen in univariate and multivariable models. Hypertension was associated with a higher rate of death in univariate analysis (HR: 1.14 [95% CI: 1.12 to 1.17]) but a lower rate of death in the multivariable analysis (adjusted HR: 0.94 [95% CI: 0.91 to 0.96]). When male and female patients were analyzed separately (Figs. 2B and 2C, Online Table 2), all comorbidities except LBBB (and hypertension in multivariable analyses) maintained their association with higher rates of mortality. In the univariate analysis, LBBB was associated with a 31% lower mortality rate in women (HR: 0.69 [95% CI: 0.67 to 0.71]) but only a 16% lower mortality rate in men (HR: 0.84 [95% CI: 0.82 to 0.85]). Controlling for comorbidities, LBBB was still associated with a 26% lower mortality rate in women (adjusted HR: 0.74 [95% CI: 0.71 to 0.77]) compared with a 15% lower mortality rate in men (adjusted HR: 0.85 [95% CI: 0.83 to 0.87]) (Fig. 2D). Evaluating the interaction of sex and LBBB demonstrated that after accounting for other comorbidities, the presence of LBBB was associated with a lower mortality in women than in men (p < ). (All interaction p values are listed in Online Table 3). In contrast, ischemic cardiomyopathy and atrial fibrillation/ flutter were associated with lower rates of death in men compared with women (adjusted HRs: 1.02 vs and 1.25 vs. 1.34, respectively). Univariate and multivariable models for HF hospitalization or death. Similar patterns were seen in all models for the combined outcome of HF hospitalization or death (Figs. 3 and 4, Online Tables 4 and 5). All comorbidities were associated with increased rates of HF hospitalization or death with the exception of LBBB, which was associated with an 18% lower rate of event (adjusted HR: 0.82 [95% CI: 0.81 to 0.83]) (Fig. 4A). As with mortality alone, the reduced rate of HF hospitalization or death associated with LBBB was more substantial in women (31% lower event rate) compared with men (16% lower event rate) (Online Table 5). This difference in the prognostic significance of conventional LBBB diagnosis according to sex remained significant after controlling for baseline characteristics (26% lower event rate in women compared with 15% in men)
5 JACC: Heart Failure Vol. 1, No. 3, 2013 June 2013: Loring et al. LBBB and Sex in Medicare CRT Patients 241 Figure 2 Forest Plots of Multivariable HRs for Death Multivariable hazard ratios (HRs) with 95% confidence intervals (CIs) for (A) the total population, (B) female patients, and (C) male patients. D demonstrates the HRs and 95% CIs for LBBB for both the female and male population independently. The CIs for these 2 estimates do not overlap. HF ¼ heart failure; RBBB ¼ right bundle branch block; other abbreviations as in Figure 1. (Fig. 4, Online Table 5). Gender interaction p values for HF hospitalization or death are listed in Online Table 6. Discussion The diagnosis of LBBB is associated with significantly greater survival in women than in men receiving CRT-D, and this discrepancy is not explained by differences in comorbidities. Men more frequently had ischemic cardiomyopathy and atrial fibrillation/flutter, which have been associated with worse CRT-D outcomes (20,21). Although differences in baseline risk profiles may contribute to the differences in CRT-D outcomes according to sex, multivariable analysis demonstrated that after accounting for baseline comorbidities, a large difference in the association of LBBB with death remained (15% lower mortality in males vs. 26% in females). Furthermore, a significant interaction between sex and LBBB confirmed that the LBBB diagnosis in and of itself carries a different prognosis for female and male CRT-D recipients. These findings suggest that the sex difference in LBBB mortality rates is independent of differences in baseline risk profiles. LBBB and CRT. When the left bundle branch is blocked, the LV lateral wall is activated significantly later than the septum, which creates dyssynchronous contraction; dyssynchrony can be minimized by CRT to improve cardiac output. Other conditions that prolong QRSD (e.g., RBBB, LV hypertrophy, intramural conduction delay) maintain coordinated LV activation by the rapidly conducting LV Purkinje system. Previous work has suggested that the reduction in
6 242 Loring et al. JACC: Heart Failure Vol. 1, No. 3, 2013 LBBB and Sex in Medicare CRT Patients June 2013: Figure 3 Kaplan-Meier Plots of Survival and Freedom From HF Hospitalization Results are stratified according to (A) sex, (B) LBBB, or (C) both. Similar to analysis with death alone, women and LBBB patients had better survival free of heart failure (HF) hospitalization or death compared with men and non-lbbb patients, respectively. Abbreviations as in Figure 1. mortality and HF hospitalizations associated with CRT may be limited to patients with LBBB (6,7,22). Retrospective analysis of the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial Cardiac Resynchronization Therapy) study found that LBBB patients receiving CRT-D had a 53% reduction in death or HF events, whereas patients with RBBB or nonspecific LV conduction delay receiving CRT-D had a 24% increase in HF events or death (although these results were not statistically significant) (6). Furthermore, the outcome was even worse in patients with nonspecific LV conduction delay than RBBB. Newly developed, stricter diagnostic criteria for LBBB suggest that many patients who receive a diagnosis for LBBB according to conventional electrocardiographic criteria (defined in this study by using the ICD-9-CM code) and do not meet the strict LBBB criteria may belong to the nonspecific LV conduction delay group (10). One study comparing CRT outcomes between patients who met strict LBBB criteria versus those who only met conventional LBBB criteria found that those meeting the strict criteria had better echocardiographic response and higher event-free survival, which was independent of QRSD (23). Although it is possible that LBBB truly has different prognostic significance according to sex, recent studies have suggested that current diagnostic criteria for LBBB misdiagnose up to one-third of patients and that this misclassification occurs more frequently in men than in women (10,17,18,24). Women have shorter normal QRSD than men ( ms vs ms, respectively) (16) in normal conduction; thus, recommendations for sex-specific LBBB criteria use a QRSD threshold of 130 ms for women and 140 ms for men (10,24). These thresholds suggest that many patients diagnosed with LBBB by using conventional criteria may have false-positive findings and that the potential misclassified population is larger in men than in women (all male patients with QRSD 120 to 140 ms vs. 120 to 130 ms for women). Therefore, it is possible that LBBB predicts better outcomes in women because among those diagnosed with LBBB, women more frequently exhibit truly dyssynchronous activation of the left ventricle and are thus more likely to benefit from resynchronization therapy. Sex differences in HF and CRT. In both LBBB and non- LBBB patients, women in the current study had a lower rate of mortality than men throughout follow-up. This finding is consistent with previous studies in both the United States and Europe, which demonstrated that women have better long-term survival after CRT than men (25 27). Although the source of this disparity cannot be determined from our study, it is possible that sex differences in true LBBB prevalence is a major factor driving the outcome disparity in men and women with LBBB. For non-lbbb patients, other studies have demonstrated that women also more frequently have nonischemic cardiomyopathies and smaller myocardial scar sizes than men, both of which are associated with better outcomes after CRT (12,13,25 28). Study limitations. The current study relied on assessing baseline characteristics and outcomes as documented by Medicare billing data and ICD-9-CM codes. It is possible that coding or entry errors may have resulted in misdiagnosis
7 JACC: Heart Failure Vol. 1, No. 3, 2013 June 2013: Loring et al. LBBB and Sex in Medicare CRT Patients 243 Figure 4 Forest Plots of Multivariable HRs for HF Hospitalization or Death Multivariable HRs with 95% CIs for (A) the total population, (B) female patients, and (C) male patients. D demonstrates the HRs and 95% CIs for LBBB for both the female and male population independently. The CIs for these 2 estimates do not overlap. Abbreviations as in Figures 1, 2, and 3. of baseline characteristics, including LBBB, previous HF hospitalization, and CRT-D implantation. In addition, some diagnostic codes are broad (e.g., 427.3x refers to atrial fibrillation or atrial flutter) and may result in overestimation or underestimation of some comorbidities. However, this possibility is equally likely in men and women, and the large sample size makes these results more robust and less prone to errors due to miscoding. In addition, previous work has demonstrated that adjudicating Medicare claims resulted in changes in <3% of claims, suggesting that the data entry errors are minimal (29). The sex differences demonstrated in this study may be the result of indirect effects from unmeasured variables. All models were designed to be robust and include all available comorbidities likely related to the outcomes. In addition, the study would be strengthened by including analysis with QRSD, New York Heart Association class, and LV ejection fraction; however, these variables are not available in Medicare billing records. Conclusions The results of this study demonstrated that among Medicare beneficiaries undergoing implantation with CRT-D, LBBB predicts better outcomes among women than men. One possible explanation for this sex disparity is that men may have more false-positive LBBB diagnoses than women. To our knowledge, this is the first time that LBBB has been shown to portend significantly better long-term survival benefit in women than men receiving CRT-D. Developing more patient-specific selection criteria for CRT-D may reduce the risks and costs associated with inappropriate therapy. Future studies should investigate appropriate
8 244 Loring et al. JACC: Heart Failure Vol. 1, No. 3, 2013 LBBB and Sex in Medicare CRT Patients June 2013: QRSD thresholds in men and women that best identify CRT-D candidates. Reprint requests and correspondence: Dr. David G. Strauss, FDA, Center for Devices and Radiological Health, New Hampshire Avenue, WO , Silver Spring, Maryland REFERENCES 1. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350: Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352: McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004;141: Al-Majed NS, McAlister FA, Bakal JA, Ezekowitz JA. Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011;154: Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;123: Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363: Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012;126: Bilchick KC, Kamath S, Dimarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation 2010;122: Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. Am J Cardiol 2011;107: Selzman K, Shein M. QRS morphology rather than QRS duration for predicting CRT response. Arch Intern Med 2011;171: Yi-Zhou X, Friedman P, Webster T, et al. Cardiac resynchronization therapy: do women benefit more than men? J Cardiovasc Electrophysiol 2012;23: Pina IL, Kokkinos P, Kao A, et al. Baseline differences in the HF- ACTION trial by sex. Am Heart J 2009;158:S Sipahi I, Carrigan TP, Rowland DY, Stambler BS, Fang JC. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011;171: Dupont M, Rickard J, Baranowski B, et al. Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. Journal of the American College of Cardiology 2012;60: Macfarlane P, Oosterom AV, Pahlm O, Kligfield P, Janse M, Camm J. Appendix 1: Normal Limits. In: Comprehensive Electrocardiology: Second Edition. London, UK: Springer-Verlag London Limited, 2011: Vassallo JA, Cassidy DM, Marchlinski FE, et al. Endocardial activation of left bundle branch block. Circulation 1984;69: Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundlebranch block. Circulation 2004;109: Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;124: Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2011;8: Boston Scientific Corporation. Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT- CRT): sponsor s executive summary, P010012/S230. Available at: Materials/MedicalDevices/MedicalDevicesAdvisoryCommittee/Cir culatorysystemdevicespanel/ucm pdf. Accessed May 30, Mascioli G, Padeletti L, Sassone B, et al. Electrocardiographic criteria of true left bundle branch block: a simple sign to predict a better clinical and instrumental response to CRT. Pacing Clin Electrophysiol 2012; 35: Strauss DG, Selvester RH. The QRS complexda biomarker that images the heart: QRS scores to quantify myocardial scar in the presence of normal and abnormal ventricular conduction. J Electrocardiol 2009;42: Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006;113: Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007; 153: Loring Z, Strauss DG, Gerstenblith G, Tomaselli GF, Weiss RG, Wu KC. Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort. Heart Rhythm 2013;10: White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol 2006;48: Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA. Utilizing Medicare claims data for real-time drug safety evaluations: is it feasible? Pharmacoepidemiol Drug Saf 2011;20: Key Words: cardiac resynchronization therapy - left bundle branch block - sex. APPENDIX For an expanded Methods section and supplemental tables, please see the online version of this paper.
Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationIt has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit
Cardiac Resynchronization Therapy may be detrimental in patients with a Very Wide QRSD > 180 ms (VWQRSD) and Right Bundle Branch Block Morphology: Analysis From the Medicare ICD Registry Varun Sundaram
More informationLarge RCT s of CRT 2002 to present
Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University Potential Conflicts
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationCardiac resynchronization therapy for mild-to-moderate heart failure
For reprint orders, please contact reprints@expert-reviews.com Cardiac resynchronization therapy for mild-to-moderate heart failure Expert Rev. Med. Devices 8(3), 313 317 (2011) Haran Burri Electrophysiology
More informationCardiac Resynchronization and Quality of Life in Patients With Minimally Symptomatic Heart Failure
Journal of the American College of Cardiology Vol. 60, No. 19, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.054
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationSex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block
Sex Differences in Long-Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block Yitschak Biton, MD; Wojciech Zareba, MD, PhD; Ilan Goldenberg,
More informationHow do I convert my CRT Non Responder into Responder?
How do I convert my CRT Non Responder into Responder? Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting Boston Scientific, Medtronic
More informationThis is What I do to Improve CRT Response for CRT Non-Responders
This is What I do to Improve CRT Response for CRT Non-Responders Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Steering Committees (unpaid) and Clinical Trials,
More informationProvocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients
Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients David E. Krummen, MD Associate Professor of Medicine University of California San Diego and VA San Diego Healthcare System
More informationCRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?
CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT? Alessandro Lipari, MD Chair and Department of Cardiology University of Study and Spedali Civili Brescia -Italy The birth of CRT in Europe, 20 years ago
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationSurvival with Cardiac-Resynchronization Therapy in Mild Heart Failure
The new england journal of medicine original article Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure Ilan Goldenberg, M.D., Valentina Kutyifa, M.D., Ph.D., Helmut U. Klein, M.D.,
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationThe Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy
Journal of the American College of Cardiology Vol. 61, No. 9, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.051
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationEffect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials
Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials Ilke Sipahi, MD, a Josephine C. Chou, MD, a Marshall Hyden, MD,
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationHF and CRT: CRT-P versus CRT-D
HF and CRT: CRT-P versus CRT-D Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief, Cardiology Section Philadelphia VA Medical Center Philadelphia, PA
More informationAuthor's Accepted Manuscript
Author's Accepted Manuscript MADIT-CRT and His Many Sons Paul A. Rogers MD, Ph.D., Daniel P. Morin MD, MPH PII: DOI: Reference: S1050-1738(15)00156-5 http://dx.doi.org/10.1016/j.tcm.2015.05.011 TCM6182
More informationFrom left bundle branch block to cardiac failure
OF JOURNAL HYPERTENSION JH R RESEARCH Journal of HYPERTENSION RESEARCH www.hypertens.org/jhr Original Article J Hypertens Res (2017) 3(3):90 97 From left bundle branch block to cardiac failure Cătălina
More informationEvaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias. Markus Kowalsky Group 11
Evaluation of Sum Absolute QRST Integral as a Clinical Marker for Ventricular Arrhythmias Markus Kowalsky Group 11 Selected Paper Ventricular arrhythmia is predicted by sum absolute QRST integral but not
More informationEBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA
Over 200,000 patients worldwide are estimated to receive a CRT device each year. However, limitations prevent some patients from benefiting. CHALLENGING PROCEDURE 5% implanted patients fail to have coronary
More informationCardiac Resynchronization ICD Therapy: What is New?
Cardiac Resynchronization ICD Therapy: What is New? Emile Daoud, MD Section Chief, Cardiac Electrophysiology Professor of Medicine The Ohio State University Normal Activation, Narrow QRS Synchrony Abnormal
More informationPrognostic Implication of the QRS Axis and its Association with Myocardial Scarring in Patients with Left Bundle Branch Block
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Prognostic Implication of the QRS Axis and its Association with Myocardial Scarring in Patients with Left Bundle
More informationWHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY?
WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY? Mary Ong Go, MD, FPCP, FPCC, FACC OUTLINE What is CRT Who needs CRT What does the
More informationJournal of the American College of Cardiology Vol. 61, No. 14, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 61, No. 14, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.020
More informationA Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE
A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE Adele Greyling Dora Nginza Hospital, Port Elizabeth SA Heart November 2017 What are the guidelines based on? MADIT-II Size:
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationCardiac Resynchronization Therapy: Improving Patient Selection and Outcomes
The Journal of Innovations in Cardiac Rhythm Management, 3 (2012), 899 904 DEVICE THERAPY CLINICAL DECISION MAKING Cardiac Resynchronization Therapy: Improving Patient Selection and Outcomes GURINDER S.
More informationBrian Olshansky, MD, FHRS,* John D. Day, MD, FHRS, Renee M. Sullivan, MD,* Patrick Yong, MSEE, Elizabeth Galle, MS, Jonathan S. Steinberg, MD, FHRS
Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial Brian
More informationIntroduction. CLINICAL RESEARCH Sudden death and ICDs
Europace (2016) 18, 1374 1382 doi:10.1093/europace/euv347 CLINICAL RESEARCH Sudden death and ICDs Reduced long-term overall mortality in heart failure patients with prolonged QRS treated with CRT combined
More informationIndications for and Prediction of Successful Responses of CRT for Patients with Heart Failure
Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure Edmund Keung, MD Clinical Chief, Cardiology Section San Francisco VAMC October 25, 2008 Presentation Outline
More informationVariations of QRS Morphology in Patients with Dilated Cardiomyopathy; Clinical and Prognostic Implications
J Cardiovasc Thorac Res, 2014, 6(2), 85-89 doi: 10.5681/jcvtr.2014.019 http://journals.tbzmed.ac.ir/jcvtr TUOMS Publishing Group Review Article Variations of QRS Morphology in Patients with Dilated Cardiomyopathy;
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationGender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy
Electrophysiology Gender and cardiac resynchronization therapy Dean Boddington Chairs: David Heaven & Belinda Green Gender and Cardiac Resynchronisation Therapy Dean Boddington Tauranga Hospital 1 Disclosure/Warning
More informationBENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT
BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT Ilan Goldenberg MD Professor of Cardiology Sheba Medical Center and Tel Aviv University, Israel University of Rochester
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19036 holds various files of this Leiden University dissertation. Author: Bommel, Rutger Jan van Title: Cardiac resynchronization therapy : determinants
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More information8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation
CARDIAC RESYCHRONIZATION THERAPY for Heart Failure James Taylor, DO, FACOS Cardiothoracic and Vascular surgery San Angelo Community Medical Center San Angelo, TX Case Presentation 64 year old female with
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationEffect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin
Effect of Ventricular Pacing on Myocardial Function Inha University Hospital Sung-Hee Shin Contents 1. The effect of right ventricular apical pacing 2. Strategies for physiologically optimal ventricular
More informationThe Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy
The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy Results from the SMART-AV Trial Michael R. Gold, MD, PhD, Ulrika Birgersdotter-Green,
More informationBSH Annual Autumn Meeting 2017
BSH Annual Autumn Meeting 2017 Presentation title: The Development of CRT Speaker: John GF Cleland Conflicts of interest: I have received research support and honoraria from Biotronik, Boston Scientific,
More informationCurrent guidelines for device-based therapy of cardiac
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II Ilan Goldenberg,
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Last Review Status/Date: June 2015 Page: 1 of 29 Resynchronization Therapy) for the Treatment Description Cardiac resynchronization therapy (CRT), which consists of synchronized pacing of the left and
More informationCardiac resynchronization therapy for heart failure: state of the art
Cardiac resynchronization therapy for heart failure: state of the art Béla Merkely MD, PhD, DSc, FESC, FACC Vice president of the European Society of Cardiology Honorary president of the Hungarian Society
More informationLONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS
LONG-TERM SURVIVAL WITH CARDIAC RESYNCHRONIZATION THERAPY IN MILD HEART FAILURE PATIENTS Ilan Goldenberg, MD, Valentina Kutyifa, MD, PhD, Helmut Klein, MD, Scott McNitt, MA, Mary Brown, MA, Arthur J. Moss,
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC RESYNCHRONISATION THERAPY ORIGINAL ARTICLE Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD,
More informationAssociation of apical rocking with super-response to cardiac resynchronisation therapy
Neth Heart J (2016) 24:39 46 DOI 10.1007/s12471-015-0768-4 Original Article Association of apical rocking with super-response to cardiac resynchronisation therapy A. Ghani P.P.H.M. Delnoy J.J.J. Smit J.P.
More informationPredictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy
CARDIAC MARKERS ORIGINAL RESEARCH Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy Ali Kazemisaeid, MD, Ali Bozorgi, MD, Ahmad Yamini Sharif,
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Last Review Status/Date: September 2016 Page: 1 of 29 Resynchronization Therapy) for the Treatment Description Cardiac resynchronization therapy (CRT), which consists of synchronized pacing of the left
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationName of Policy: Bi-Ventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Name of Policy: Bi-Ventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure Policy #: 055 Latest Review Date: April 2014 Category: Surgery Policy Grade: A Background/Definitions:
More informationCardiac Resynchronization Therapy Guidelines and Missing Groups
Cardiac Resynchronization Therapy Guidelines and Missing Groups Frank Pelosi, Jr., MD, FACC, FHRS Director, Cardiac Electrophysiology Fellowship Associate Professor of Medicine University of Michigan Health
More informationPerspective. Open Access. András Vereckei 1, Gábor Katona 1, Zsuzsanna Szelényi 1, Gábor Szénási 2, Bálint Kozman 3, István Karádi 1.
Journal of Geriatric Cardiology (2016) 13: 118 125 2016 JGC All rights reserved; www.jgc301.com Perspective Open Access The role of electrocardiography in the elaboration of a new paradigm in cardiac resynchronization
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationRate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.
Article ID: WMC004618 ISSN 2046-1690 Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications. Peer review status: No Corresponding
More informationLONGITUDINAL SURVEILLANCE REGISTRY OF ACUITY SPIRAL LEAD
CLINICAL SUMMARY LONGITUDINAL SURVEILLANCE REGISTRY OF ACUITY SPIRAL LEAD CAUTION: Federal law restricts this device to sale by or on the order of a physician trained or experienced in device implant and
More informationBi-Ventricular pacing after the most recent studies
Seminars of the Hellenic Working Groups February 18th-20 20,, 2010, Thessaloniki, Greece Bi-Ventricular pacing after the most recent studies Maurizio Lunati MD Director EP Lab & Unit Cardiology Dpt. Niguarda
More informationNonischemic cardiomyopathy, LVEF 31-35%, no prior implant, SR for ANY of the following:
Cigna Medical Coverage Policy Subject Biventricular Pacing/Cardiac Resynchronization Therapy (CRT) Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 17 References...
More informationΕνδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;
Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή; Άννα Κωστοπούλου Επιμελήτρια Α Ωνάσειο Καρδιοχειρουργικό Κέντρο Τμήμα Ηλεκτροφυσιολογίας
More informationDevices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine
Devices and Other Non- Pharmacologic Therapy in CHF Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine Disclosure None University of Miami vs. OSU Renegade Miami football
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationBiventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure
Biventricular Pacemakers (Cardiac Resynchronization Therapy for the Treatment of Heart Failure 2.02.10 Biventricular Pacemakers (Cardiac Resynchronization Therapy for the Treatment of Heart Failure Policy
More informationCardiac Resynchronization in Mildly Symptomatic Heart Failure Patients
Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients 6 Paolo Pieragnoli, Giuseppe Ricciardi, Gemma Filice, Antonio Michelucci and Luigi Padeletti University of Florence, Italy 1. Introduction
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationShocks burden and increased mortality in implantable cardioverter-defibrillator patients
Shocks burden and increased mortality in implantable cardioverter-defibrillator patients Gail K. Larsen, MD, MPH,* John Evans, MD, William E. Lambert, PhD,* Yiyi Chen, PhD,* Merritt H. Raitt, MD* From
More informationArbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia
THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical
More informationSupplementary Online Content
Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online
More informationA bs tr ac t. n engl j med 363;25 nejm.org december 16,
The new england journal of medicine established in 1812 december 16, 2010 vol. 363 no. 25 Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure Anthony S.L. Tang, M.D., George A. Wells,
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationCRT: whom does it benefit?
CRT: whom does it benefit? Francisco Leyva BSH Revalidation and Training 2018 Queen Elizabeth Hospital NICE guidelines for CRT LVEF 35% NYHA class I II III IV QRS
More informationImplantable cardioverter-defibrillators and cardiac resynchronization therapy
Implantable cardioverter-defibrillators and cardiac resynchronization therapy Johannes Holzmeister, MD University Hospital Zurich, Zurich, Switzerland Frontiers of heart failure controversies, ESC - Paris
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationThe Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease
Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031
More informationIs QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?
Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients? Data from REVERSE C Thébault 1, M Gold 2, C Linde 3, WT Abraham 4, C Leclercq 1,
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationORIGINAL REPORTS: CARDIOVASCULAR DISEASE AND RISK FACTORS
ORIGINAL REPORTS: CARDIOVASCULAR DISEASE AND RISK FACTORS SOCIOECONOMIC AND ETHNIC DISPARITIES IN THE USE OF BIVENTRICULAR PACEMAKERS IN HEART FAILURE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION
More informationG Lin, R F Rea, S C Hammill, D L Hayes, P A Brady
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA Correspondence to: Dr Peter A Brady, MD, FRCP, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA; brady.peter@mayo.edu Accepted
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19036 holds various files of this Leiden University dissertation. Author: Bommel, Rutger Jan van Title: Cardiac resynchronization therapy : determinants
More informationImpact of QRS duration and morphology on CRT effectiveness
Impact of QRS duration and morphology on CRT effectiveness Dr Tim Betts MD MBChB FRCP Consultant Cardiologist & Electrophysiologist Oxford Heart Centre, John Radcliffe Hospital Oxford University Hospitals
More information1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and
1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,
More informationUpgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016
Upgrade to Resynchronization Therapy Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016 Event Free Survival (%) CRT Cardiac resynchronization therapy (CRT)
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationPatient-assessed short-term positive response to cardiac resynchronization therapy is an independent predictor of long-term mortality
Europace (2014) 16, 1603 1609 doi:10.1093/europace/euu058 CLINICAL RESEARCH Pacing and resynchronization therapy Patient-assessed short-term positive response to cardiac resynchronization therapy is an
More informationPrognostic Implication of QRS Variability during Hospitalization in Patients with Acute Decompensated Heart Failure
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Prognostic Implication of QRS Variability during Hospitalization in Patients with Acute Decompensated Heart Failure
More informationThe Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study
The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study Taya V. Glotzer, MD; Emile G. Daoud, MD; D. George Wyse, MD, PhD; Daniel
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationCardiac Resynchronization in Patients With Atrial Fibrillation
Journal of the American College of Cardiology Vol. 52, No. 15, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.06.043
More information